Cell vaccines articles within Nature Communications

Featured

• Article
  04 January 2024 | Open Access

  Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines

  Here the authors report an exploratory analysis of a clinical trial that tested different influenza virus vaccination platforms. The results show that multiple seasons of recombinant or cell-based influenza vaccinations may be needed to redirect antibody responses away from immune memory to egg-adapted epitopes and refocus on epitopes on the circulating viruses.

  • Feng Liu
  • , F. Liaini Gross
  •  & Min Z. Levine

• Article
  26 July 2023 | Open Access

  Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation

  Whole autologous tumor cell vaccine (TCV) has been proposed as a tool for cancer immunotherapy. Here the authors describe the design of a TCV platform based on photothermal nanoparticle-loaded tumor cells, triggering NIR laser irradiation induced anti-tumor immune responses at the vaccination site.

  • Jiaqi Meng
  • , Yanlin Lv
  •  & Wei Wei

• Article
  14 October 2020 | Open Access

  Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

  The folate receptor alpha (FRα) is overexpressed in the majority of high-grade serous ovarian cancers and has been proposed as a candidate vaccine antigen. Here the authors report the safety and immunogenicity of Th17-inducing dendritic cells pulsed with FRα-derived epitopes in an early phase I clinical trial with ovarian cancer patients.

  • Matthew S. Block
  • , Allan B. Dietz
  •  & Martin J. Cannon

• Article
  26 July 2019 | Open Access

  Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans

  Here, Khurana et al. report the results of a phase 4 clinical trial with three FDA approved influenza vaccines and show that repeat influenza vaccination results in reduced antibody affinity maturation to hemagglutinin domain 1 irrespective of vaccine platform.

  • Surender Khurana
  • , Megan Hahn
  •  & Hana Golding

• Article
  22 May 2017 | Open Access

  Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy

  Tumour-specific T cells can be expandedin vitroand adoptively transferred for therapy, but this strategy is limited by induction of short-lived T cell populations. Here the authors activate Notch signalling in cultured mouse or human T cells, resulting in the production of a long-lived stem cell memory T cell population that can fight tumours in mice.

  • Taisuke Kondo
  • , Rimpei Morita
  •  & Akihiko Yoshimura

• Article
  22 December 2016 | Open Access

  Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy

  A delay in T cell responses is postulated as a possible explanation for the limited efficacy of vaccines against tuberculosis. Here the authors demonstrate this T-cell block and remove it by activating endogenous dendritic cells or delivering activated dendritic cells to the lungs, enhancing immunity of mice toMycobacterium tuberculosis.

  • Kristin L. Griffiths
  • , Mushtaq Ahmed
  •  & Shabaana A. Khader